​

iTeos Therapeutics Ownership | Who Owns iTeos Therapeutics?

OverviewForecastRevenueFinancialsChart

iTeos Therapeutics Ownership Summary

iTeos Therapeutics is owned by 85.48% institutional investors, 1.14% insiders, and 13.39% retail investors. Blackrock is the largest institutional shareholder, holding 10.41% of ITOS shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.51% of its assets in iTeos Therapeutics shares.

ITOS Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockiTeos Therapeutics85.48%1.14%13.39%
SectorHealthcare Stocks 279.19%10.62%-189.81%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock3.73M10.41%$55.37M
Blackrock funding, inc. /de3.80M8.81%$29.20M
Boxer capital2.95M8.22%$43.73M
Mpm asset management2.74M6.35%$21.03M
Bvf inc/il2.33M5.39%$17.86M
Ra capital management2.09M4.85%$16.07M
Jpmorgan chase2.07M4.80%$15.89M
Bioimpact capital1.75M4.05%$13.41M
Vanguard group1.63M3.79%$12.55M
Morgan stanley1.09M3.04%$16.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mpm asset management2.74M16.91%$21.03M
Boxer capital2.95M2.30%$43.73M
Bioimpact capital1.75M1.90%$13.41M
Stonepine capital management110.00K0.68%$844.80K
Bvf inc/il2.33M0.61%$17.86M
Almitas capital275.12K0.46%$2.11M
683 capital management918.12K0.44%$7.05M
Vestal point capital, lp900.00K0.41%$6.91M
Dafna capital management188.35K0.37%$1.45M
Ra capital management2.09M0.21%$16.07M

Top Buyers

HolderShares% AssetsChange
Bvf inc/il2.33M0.61%2.33M
Jpmorgan chase2.07M0.00%1.60M
Boxer capital2.95M2.30%1.14M
Citigroup853.78K0.00%833.59K
Caption management509.83K0.04%509.83K

Top Sellers

HolderShares% AssetsChange
Tang capital management221.72K0.11%-2.19M
Ecor1 capital---1.61M
Braidwell lp---1.16M
Ra capital management2.09M0.21%-1.09M
Candriam s.c.a.---769.21K

New Positions

HolderShares% AssetsChangeValue
Bvf inc/il2.33M0.61%2.33M$17.86M
Almitas capital275.12K0.46%275.12K$2.11M
Eversept partners, lp220.20K0.15%220.20K$1.69M
Bnp paribas arbitrage, snc60.08K0.00%60.08K$461.41K
Clear harbor asset management12.50K0.01%12.50K$96.00K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-5.00
Parallel advisors-11.00
Farther finance advisors-19.00
Rothschild investment-25.00
Capital performance advisors llp-30.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025133-6.99%36,961,1108.28%851.36%61-19.74%44-4.35%
Dec 31, 2024141-9.62%34,049,312-6.92%781.10%74-11.90%469.52%
Sep 30, 202415511.51%36,568,9141.19%840.83%8312.16%425.00%
Jun 30, 20241381.47%36,138,0164.70%1001.09%7337.74%40-25.93%
Mar 31, 2024136-0.73%34,517,358-1.12%961.01%53-29.33%5435.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv961.13K2.51%14.70K
Vanguard US Total Market Shares ETF855.64K2.24%-413.20K
iShares Russell 2000 ETF694.36K1.81%339.00
BlackRock Advantage Small Cap Core Instl599.28K1.57%-
SPDR® S&P Biotech ETF544.15K1.49%7.73K
Candriam Eqs L Biotech C USD Cap535.59K1.47%-
Vanguard Institutional Extnd Mkt Idx Tr428.06K1.12%-
JPMorgan Small Cap Value I364.93K0.95%-
CREF Stock R1299.33K0.78%-27.07K
DFA US Targeted Value I274.69K0.72%9.03K

Recent Insider Transactions

DateNameRoleActivityValue
Jun 10, 2025Detheux Michel Chief Executive OfficerSell$439.71K
Jun 09, 2025Detheux Michel Chief Executive OfficerSell$440.14K
Jun 10, 2025Detheux Michel Chief Executive OfficerSell$84.17K
Jun 09, 2025Detheux Michel Chief Executive OfficerSell$84.25K
Jun 05, 2025Detheux Michel Chief Executive OfficerSell$85.26K

Insider Transactions Trends

DateBuySell
2025 Q2216
2025 Q1--
2024 Q41-
2024 Q3--
2024 Q21-

ITOS Ownership FAQ

Who Owns iTeos Therapeutics?

iTeos Therapeutics shareholders are primarily institutional investors at 85.48%, followed by 1.14% insiders and 13.38% retail investors. The average institutional ownership in iTeos Therapeutics's industry, Biotech Stocks , is 63.96%, which iTeos Therapeutics exceeds.

Who owns the most shares of iTeos Therapeutics?

iTeos Therapeutics’s largest shareholders are Blackrock (3.73M shares, 10.41%), Blackrock funding, inc. /de (3.8M shares, 8.81%), and Boxer capital (2.95M shares, 8.22%). Together, they hold 27.44% of iTeos Therapeutics’s total shares outstanding.

Does Blackrock own iTeos Therapeutics?

Yes, BlackRock owns 10.41% of iTeos Therapeutics, totaling 3.73M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 55.37M$. In the last quarter, BlackRock decreased its holdings by -384K shares, a -9.33% change.

Who is iTeos Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is iTeos Therapeutics’s biggest shareholder by percentage of total assets invested, with 16.91% of its assets in 2.74M iTeos Therapeutics shares, valued at 21.03M$.

Who is the top mutual fund holder of iTeos Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of iTeos Therapeutics shares, with 2.51% of its total shares outstanding invested in 961.13K iTeos Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools